Search Contract Opportunities

Notice of Intent: Program to Ensure COVID-19 Vaccination and Therapeutics Coverage for the Uninsured Post-Commercialization

Type: Presolicitation • ID: COV19-1395X-VacTher
By the Time It's in SAM, It's Probably too Late

Find opportunities months earlier with HigherGov forecasts

Free Trial Schedule Demo

Description

The Centers for Disease Control and Prevention (CDC) Office of Readiness and Response (ORR) in Atlanta, Georgia, intends to negotiate three sole source awards by modification to CDC's existing Increasing Community Access to Testing (ICATT) contracts with CVS Pharmacy Inc., Walgreen Co., and E3HealthSolutions, LLC (eTrueNorth) under the authority of Federal Acquisition Regulation (FAR) Subpart 6.302-1, Other Than Full and Open Competition procedures and 41 U.S.C. 3304(a)(1). These modifications will serve to fulfill a single CDC requirement of acquiring COVID-19 Vaccination and Therapeutics Services to provide pharmacy-based services to uninsured adults in low access and areas of low vaccination coverage. This requirement will serve as a temporary solution by providing ongoing access to COVID-19 vaccines and therapeutics once commercialization occurs and while the pending Vaccine for Adults Proposal is considered by Congress. Only CVS, Walgreens, and eTrueNorth provide the already established pandemic-response pharmacy infrastructure and resources under the ICATT COVID-19 testing contracts; have the ability to administer vaccines through pharmacy and pharmacy-partner sites; and provide the combined geographic coverage needed to reach target uninsured populations.

This is a notice of intent and is not a request for competitive quotes or proposals. No solicitation is available. Firms that believe they can meet the requirement are encouraged to identify themselves and provide a substantive statement with descriptive literature and any other supporting information to the Contracting Officer within fourteen (14) days of publication of this notice. All information received within 14 days of publication of this synopsis will be considered by the Government to determine if additional firm(s) can meet the Government's requirements and is/are capable of providing the necessary services to the target population using effective and efficient infrastructure cohesive with the existing pandemic response. Responses to this posting must be submitted in writing via e-mail only. A determination not to compete the described requirement based upon responses to this notice is solely within the discretion of the Federal Government. Information received will be considered solely for the purpose of determining whether or not to conduct a competitive procurement. Any questions or comments should be directed via e-mail ONLY to Samantha Bily at QNB7@cdc.gov. Thank you for your interest.

Overview

Response Deadline
May 11, 2023, 1:00 p.m. EDT Past Due
Posted
April 27, 2023, 12:43 p.m. EDT
Set Aside
None
Place of Performance
Atlanta, GA 30333 USA
Source
SAM

Est. Level of Competition
Sole Source
Odds of Award
21%
On 4/27/23 Centers for Disease Control and Prevention issued Presolicitation COV19-1395X-VacTher for Notice of Intent: Program to Ensure COVID-19 Vaccination and Therapeutics Coverage for the Uninsured Post-Commercialization due 5/11/23. The opportunity was issued full & open with NAICS 62199 and PSC Q701.
Primary Contact
Name
Samantha Bily   Profile
Email
Phone
None

Documents

Posted documents for Presolicitation COV19-1395X-VacTher

Incumbent or Similar Awards

Potential Bidders and Partners

Awardees that have won contracts similar to Presolicitation COV19-1395X-VacTher

Similar Active Opportunities

Open contract opportunities similar to Presolicitation COV19-1395X-VacTher

Additional Details

Source Agency Hierarchy
HEALTH AND HUMAN SERVICES, DEPARTMENT OF > CENTERS FOR DISEASE CONTROL AND PREVENTION > CDC OFFICE OF ACQUISITION SERVICES
FPDS Organization Code
7523-00254
Source Organization Code
100188028
Last Updated
May 26, 2023
Last Updated By
qnb7@cdc.gov
Archive Date
May 27, 2023